Sam Hawgood, MBBS, Chancellor, UC San Francisco

Hawgood 2014 - half.jpg

Sam Hawgood, MBBS, is the Chancellor and the Arthur and Toni Rembe Rock Distinguished Professor at the University of California, San Francisco (UCSF).

Hawgood was dean of the UCSF School of Medicine and vice chancellor for medical affairs from 2009-2014, after assuming the role of interim dean in December of 2007. His distinguished career at UCSF includes serving as chair of the Department of Pediatrics and associate director of the Cardiovascular Research Institute

Hawgood joined UCSF as a research fellow in 1982, and maintained his laboratory through 2015. His focus on the proteins associated with pulmonary surfactant has led to a multi-disciplinary Program Project Grant from the National Heart, Lung and Blood Institute, which has supported his work continuously since then and gained him an international reputation in neonatology research.

Numerous organizations and publications have recognized Hawgood’s scientific contributions over the past few decades. Hawgood is a member of the American Academy of Pediatrics and the American Association of Physicians, and in 2010 was elected to the Institute of Medicine (IOM), part of the National Academy of Sciences.

Hawgood maintained an active presence in clinical medicine, including serving first as division chief of the Division of Neonatology, then as chair of Pediatrics and physician-in-chief of the UCSF Benioff Children’s Hospital prior to becoming dean. From 2004 through 2014 he was also president of the UCSF Medical Group, the faculty association that represents more than 1,800 physicians.

As dean of the School of Medicine, he oversaw an organization with an operating budget of more than $1.7 billion, nearly 8,000 faculty and staff, and around 3,655 medical and graduate students, residents, fellows and postdoctoral scholars.

Under his leadership, the school became the top medical school in the nation in research funding from the National Institutes of Health ($439.6 million in 2013), with many of its departments also leading the nation in their fields, reflecting the caliber of scientific research on campus. In that time, the school also became the only medical school in the nation to rank in the top five in both research- and primary care education (#4 in each), in the US News & World Report’s annual assessment of graduate schools.

The school’s clinical faculty is renowned for world-class medical care through its practice in the top-ranked UCSF Medical Center, UCSF Benioff Children’s Hospital, Langley Porter Psychiatric Institute, San Francisco General Hospital & Trauma Center, and the San Francisco Veterans’ Administration Medical Center.

As chancellor, Hawgood oversees the entire $5.45 billion UCSF enterprise, which also includes top-ranking schools of dentistry, nursing and pharmacy, as well as a graduate division and affiliated hospitals.

A native of Australia, Hawgood graduated medical school with First Class Honors from the University of Queensland in Brisbane. He trained in pediatrics as a resident, followed by specialization in neonatology.
 

Jeffrey Shuren, MD, JD, Director, Center for Devices and Radiological Health, FDA

Shuren0065.jpg

Jeffrey Shuren, MD, JD is the Director of the Center for Devices and Radiological Health (CDRH) at FDA. He previously served as Acting Center Director. Dr. Shuren has held various policy and planning positions within FDA from 1998 to 2009, including Acting Deputy Commissioner for Policy, Planning, and Budget; Associate Commissioner for Policy and Planning; and Special Counsel to the Principal Deputy Commissioner. Dr. Shuren is board certified in Neurology and served as an Assistant Professor of Neurology at the University of Cincinnati. In 1998, Dr. Shuren joined FDA as a Medical Officer in the Office of Policy. In 2000, he served as a detailee on the Senate HELP Committee. In 2001, he became the Director of the Division of Items and Devices in the Coverage and Analysis Group at the Centers for Medicare and Medicaid Services. From 1998 to 2003, he served as a Staff Volunteer in the National Institutes of Health’s National Institute of Neurological Disorders and Stroke Cognitive Neuroscience Section supervising and designing clinical studies on human reasoning. Dr. Shuren returned to FDA as the Assistant Commissioner for Policy in 2003, and assumed his current position in September 2009.

Christine Winoto, Founder and Director, Rosenman Institute; Deputy Director, QB3

_OR_1915.jpg

Christine Winoto, Director of the Rosenman Institute, Deputy Director of QB3, Co-Founder and Venture Partner at MedTech Venture Partners I LLP, manages the QB3 Life Science Pitch Summit program, the QB3-JPMorgan Chase program for women and diversity in life sciences, and QB3 operations. Before joining QB3, she developed business plan and marketing strategy and capital planning for Kaiser Permanente and managed business development at Genencor. In addition to consulting for startups and venture capital, she has held R&D and operations positions in medical device companies including Physiometrix (IPO, then acquired by Hospira), Cardiovasc and Heartport. Christine also worked in mergers and acquisitions for a European investment bank. Christine holds an MBA from Erasmus University in the Netherlands and a BS in food chemistry from the University of Wisconsin, Madison.